Similarly, DPP-4 inhibitors have also shown promise in managing Huntington disease [55] and epilepsy owing to their significant potentiation of GABAergic neurotransmission, likely via their indirect GLP-1 receptor agonism [56]. The gene discussed is GLP1R; the disease is juvenile Huntington disease.